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ABSTRACT 
Loperamide, an opiate agonist of high specificity for p-receptors, 
was recently reported to suppress ACTH and cortisol levels in normal 
subjects, but not in patients with proven ACTH-dependent Cushing’s 
disease. However, there is little information on the site of action of 
loperamide in the hypothalamo-pituitary-adrenal axis of man. We 
investigated the effect of loperamide on pituitary hormone secretion in 
uiuo and in vitro. In seven normal subjects, basal ACTH plasma levels 
were significantly suppressed 3 h after loperamide administration (16 
mg, orally) from 5 + 1 to 2 f  0 pmol/L (P < 0.0001). After the combined 
pituitary stimulation test (100 pg human CRH, 100 rg GnRH, 100 pg 
GH-releasing hormone, and 200 pg TRH), the ACTH peak (maximum 
increase at 30 min) was significantly blunted by loperamide from 9 + 
1 to 4 of: 1 pmol/L (P < 0.001) and the area under the curve of ACTH 
from O-120 min was reduced from 35 + 5 to 23 + 4 pmol/L.2 h (P < 
0.05). In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the 
ACTH peak nor the area under the curve of ACTH was affected by 
loperamide. In six patients with Cushing’s disease and one patient with 
secondary adrenal insufficency due to hypothalamic failure, neither 
basal ACTH and cortisol levels nor CRH-stimulated levels were influ- 
enced by loperamide. In four cultured human corticotropic adenomas, 
loperamide was not able to reduce basal and CRH-induced ACTH 
secretion. In summary, loperamide is able to reduce basal and CRH- 
induced ACTH and cortisol levels in normal subjects, but not in 
patients with Cushing’s disease or secondary adrenal failure of hypo- 
thalamic origin. Loperamide has no significant effect on insulin-hypo- 
glycemia-induced ACTH and cortisol levels and, therefore, no effect 
on stress-induced elevation of cortisol levels. Loperamide might act at 
a suprapituitary site in man in viuo, but, nevertheless, a pituitary site 
cannot be excluded. (J Clin Endocrirwl Metab 75: 552-557,1992) 
T HE ANTIDIARRHEAL drug loperamide is an agent of the piperidine class known to act as an opiate agonist of 
high specifity for p-receptors (1, 2). Loperamide was recently 
reported to suppress ACTH and cortisol levels in normal 
subjects and patients with Addison’s disease, but not in 
patients with proven ACTH-dependent Cushing’s disease 
(3-5). The suppressive effect of loperamide on ACTH secre- 
tion was shown to be reversible by naloxone (4). Loperamide 
also modified the ACTH responses to CRH and lysine va- 
sopressin in patients with Addison’s disease (6). With regard 
to ACTH secretion, these findings are similar to those for a 
number of F-opiate agonists, where secretion was suppressed 
in normal subjects but not in patients with Cushing’s disease 
(7-10). However, in spite of the well established suppressive 
effect of opiate alkaloids and peptides on ACTH secretion, 
their precise site of action has not been identified up to now. 
While some investigations suggest a direct pituitary site of 
action (9, ll), others postulate a suprapituitary modulation 
of some CRH-potentiating factors by the opioid system (10, 
12). 
One aim of our study was to elucidate the site of action of 
loperamide in the hypothalamo-pituitary-adrenal axis of 
man. While administration of releasing hormones stimulates 
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hormone secretion at the pituitary level (13), insulin-induced 
hypoglycemia activates the whole hypothalamo-pituitary- 
adrenal axis and stimulates suprapituitary centers (14, 15). 
Therefore, the combination of a specific hypothalamic and 
pituitary stimulation test should make it possible to localize 
the site of action of loperamide. Moreover, no data exist to 
indicate whether therapeutically or diagnostically used high 
dose administration of loperamide may carry the risk of a 
reduced adrenocortical responsivness to stress in an ill pa- 
tient. The insulin-hypoglycemia test was performed to ad- 
dress this problem. Additional information about the action 
of loperamide was sought by investigating the effect of this 
drug on CRH-induced ACTH secretion in patients with 
Cushing’s disease in vivo and in human corticotrophic ade- 
nomas in vitro. 
Materials and Methods 
Materials 
Loperamide was obtained from Janssen (Neuss, Germany). Human 
(h) CRH was purchased from Bissendorf Peptide GmbH (Wedemark, 
Germany). Regular human insulin was obtained from Novo Industrie 
GmbH (Mainz, Germany). 
Subjects 
The combined pituitary stimulation test and insulin-hypoglycemia 
test was performed in seven healthy volunteers, aged 20-28 yr. The two 
females and five males had normal body weight according to the Broca 
index. All were free from any current life stress situations, physical 
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illness, and medication. 
The CRH stimulation test was performed in six female patients, aged 
20-45 yr, with proven Cushing’s disease and in one male patient (47 
yr) with secondary adrenal insufficency. 
The diagnosis of Cushing’s disease was made by the following 
endocrine evaluation. Mean plasma cortisol concentrations, derived from 
five measurements at 4- to 5-h intervals within a 24-h period, were 
determined in the preoperative period and showed a cancelled diurnal 
rhythm of secretion. The range of mean plasma cortisol concentrations 
was 480-950 nmol/L (normal, 250-650 nmol/L). After the low dose 
dexamethasone suppression test (2 mg/day), there was a lack of suppres- 
sion of cortisol secretion. In the insulin-hypoglycemia test (0.15 IU/kg 
BW), patients did not show an appropriate cortisol secretory response. 
The range of basal plasma ACTH concentrations was 7-24 pmol/L 
(normal, 4-17 pmol/L). All patients responded to a large dose of dexa- 
methasone (8 mg/day) with a significant decrease in plasma cortisol 
levels. In addition, every patient was subjected to a sinus petrosus 
inferior catheterization in combination with a CRH stimulation test for 
determination of pituitary origin and localization of ACTH secretion. 
The radiological investigation consisted of a nuclear magnetic resonance 
scan. All patients were cured after transsphenoidal microsurgery. 
The patient with secondary adrenal insufficency due to a hypotha- 
lamic origin of his disease had no ACTH response to the insulin- 
hypoglycemia test (data not shown). However, -a large rise in ACTH 
secretion was observed from a low basal level after the CRH stimulation 
test, Cortisol levels were not detectable. The hydrocortisone substitution 
(25 mg/day) was discontinued on the days of the tests. 
All subjects were familiar with the nature of the study and had given 
written informed consent. Each person acted as his own control, and 
cross-over studies were performed at random at least a week apart. 
Protocols 
Tests started at 0730 h (-210 min) after an overnight fast. The cubital 
vein was canulated and kept open with iv 0.9% saline. At 0800 h (-180 
min), 16 mg loperamide in liquid form (8 mL) or placebo was given 
orally. The combined pituitary stimulation test was performed with 100 
pg hCRH, 100 rg GnRH, 100 rg GH-releasing her*mone (GHRH), and 
200 YP. TRH. The CRH stimulation test was uerformed with 100 11p. 
hCRHy and the insulin-hypoglycemia test with’ 0.15 IV/kg BW regulai 
human insulin. Each agent was administered iv at 1100 h (0 min). Blood 
samples were collected between -180 and 120 min at 15- to 30-min 
intervals. Hypoglycemia was regarded as adequate if the blood glucose 
level was decreased to below 2.2 mmol/L and typical clinical signs were 
documented. 
Hormone measurements 
ACTH was measured with a commercial immunoradiometric assay 
kit from Nichols Institute (San Juan Capistrano, CA). Intra- and inter- 
assay variabilities were 6.9% and 13.3%, respectively. The detection 
limit was 1 pmol/L. Normal values were 3-11 pmol/L. Cortisol was 
measured by a specific RIA (16). Intra- and interassay variabilities were 
3.6% and 5.0%, respectively. The detection limit was 30 nmol/L. Normal 
values ranged from 140-550 nmol/L. PRL, LH, FSH, GH, and TSH were 
measured by double antibody RIAs (17). 
Human corticotropic adenoma cell culture 
Cell culture was performed as described recently by Stalla et al. (18). 
In brief, after transsphenoidal surgery, adenoma tissue was transported 
to the laboratory in sterile culture medium. Routinely, the tumor trans- 
port medium was assayed for all anterior pituitary hormones. The four 
tumors were selected for these studies because they had no detectable 
levels of LH, FSH, TSH, GH, and PRL, in contrast to high ACTH levels 
(>2000 pmol/L) in the transport medium. The tissue was mechanically 
and enzymatically dispersed. Cells were diluted to a density of 1.0 x 
lo5 cells/ml and distributed in 24-well tissue culture plates. The plates 
were placed in a humidified CO, incubator for 4-6 days. Afterwards, 
the monolayers were washed with Dulbecco’s Modified Eagle’s Medium 
containing 0.5 g/L BSA. The hCRH standard (2 nM) and loperamide (1 
and 10 PM) were added in small volumes (50 rL). Cells were preincu- 
bated for 30 min with loperamide and then incubated together with 
CRH or medium alone for a further 180 min. Then medium was removed 
for ACTH measurement by a RIA, as described previously (18). 
Statistics 
Statistics were performed by analysis of variance in combination with 
the Scheffe test. All data are shown as the mean + SE. To eliminate 
intervariability between subjects, the data in Figs. 1, 2, 3, and 5 are 
shown as a percentage of the basal control value (100%). Three different 
parameters were used to estimate the basal and stimulated hormone 
levels in the in viva studies: 1) 0’, basal level at 0 min; 2) A30’, hormone 
level 30 min after stimulation minus basal level at 0 min; and 3) AUC, 
area under the curve from O-2 h after stimulation minus basal level at 
0 min. 
Results 
In vivo studies 
Normal subjects. In the combined pituitary stimulation test, 
the basal plasma ACTH levels at -180 min were almost 
identical in the loperamide VS. placebo group. While the basal 
ACTH level did not change in the placebo group during the 
following 3 h, it significantly declined early (-120 min) 
during loperamide treatment and showed a nadir of 43 + 
6% VS. 100 + 0% (5 + 1 pmol/L) at 0 min (P < 0.001). After 
combined pituitary stimulation, the peak ACTH levels in the 
loperamide VS. placebo group differed significantly up to 60 
min (155 + 29% ZIS. 319 + 54% at 45 min, respectively; P < 
0.05). At 120 min, ACTH levels in both groups had returned 
to basal values. Furthermore, the ACTH increase (A30’) was 
significantly blunted by loperamide from 9 f 1 to 4 f 1 
pmol/L (P < O.OOl), and the AUC of ACTH was significantly 
reduced from 35 & 5 to 23 + 4 pmol/L.2 h (P < 0.05; Fig. 
1). 
Basal cortisol plasma levels at -180 min were similar in 
the loperamide VS. placebo group. Even at -120 min, a 
significant difference between the treatment groups could be 
observed with respect to cortisol secretion. At 0 min, cortisol 
secretion was suppressed by loperamide to 39 + 5% VS. 100 
+ 0% (300 + 60 nmol/L; P < 0.01). After combined pituitary 
stimulation, the cortisol levels during loperamide treatment 
showed significant differences from those in the placebo 
group at each time up to 120 min. In both groups, cortisol 
levels reached their maximum values at 60 min (172 + 27% 
VS. 252 f 23%; P < 0.01) and returned to almost basal values 
at 120 min. In addition, the cortisol increase (A30’) was 
significantly blunted by loperamide from 330 + 30 to 170 + 
30 nmol/L (P < 0.05), whereas the decline in the AUC was 
not significant (Fig. 1). 
The basal level of PRL at -180 min was 10 + 1 pg/L and 
declined in the placebo group to 5 f 0 pg/L at 0 min; in 
contrast, in the loperamide group, PRL stayed at the elevated 
level of 9 + 1 pg/L (P < 0.0001). Stimulated PRL levels as 
well as basal and stimulated hormone levels of LH, FSH, 
GH, and TSH did not show any significant differences be- 
tween placebo and loperamide treatment groups (data not 
shown). 
In the insulin-hypoglycemia test, the basal ACTH values 
at -180 min were almost identical in the loperamide VS. 
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FIG. 1. Effects of loperamide and placebo on plasma ACTH and cor- 
tisol (mean f  SE) before and after a combined bolus injection of 100 
pg hCRH, 100 pg GnRH, 100 fig GHRH, and 200 pg TRH in seven 
normal subjects. Loperamide (16 mg) or placebo was given orally at 
-180 min. hCRH, GnRH, GHRH, and TRH were given at 0 min. Data 
are shown as a percentage of the basal value at 0 min in the placebo 
group (100%). The corresponding ACTH value was 5 + 1 pmol/L, and 
the corresponding cortisol value was 300 f  60 nmol/L. Stars indicate 
times at which a significant difference occurred between loperamide 
and placebo treatments by the Scheffe test (*, P < 0.05; *+, P < 0,Ol: 
***, P < 0.001). 
placebo group. The basal ACTH levels in the placebo group 
showed a slight decrease for the next 3 h, while in the 
loperamide group, ACTH levels were significantly dimin- 
ished as early as -60 min and reached 51 +- 3% vs. 100 f 
0% (4 f 0 pmol/L) at 0 min (P < 0.0001). After insulin 
injection, there was a delayed, but overwhelming, ACTH 
increase in the placebo group as well as in the loperamide 
group (977 + 128% VS. 730 f 103% at 45 min), which could 
not be significantly suppressed by loperamide at any time. 
Peak ACTH was about 3-4 times higher than that in the 
combined pituitary stimulation test. In the second hour after 
insulin injection, ACTH levels in the loperamide and placebo 
group were nearly identical and reached basal levels at 120 
min. Also, there was no significant decline of the ACTH 
increase (A30’) and AUC after loperamide treatment com- 
pared to those after placebo administration (Fig. 2). 
Basal cortisol levels at -180 min were about 20% higher 
in the loperamide than in the placebo group, but were 
diminished significantly at 0 min 62 + 7% vs. 100 + 0% (250 
f 30 nmol/L; P < 0.01). Corresponding to the ACTH values, 
there was a delayed cortisol increase during hypoglycemia. 
At 60 min, cortisol levels reached their maximum of 312 -I- 
28% in the placebo group and 292 + 23% in the loperamide 
group and did not return to basal levels until 120 min. At no 
time during hypoglycemia were the cortisol levels blunted 
significantly by loperamide. Loperamide also failed to signif- 
icantly decrease the cortisol increase (A30’) or the AUC (Fig. 
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FIG. 2. Effects of loperamide and placebo on plasma ACTH and cor- 
tisol (mean + SE) before and after a bolus injection of 0.15 IV/kg BW 
regular human insulin in seven normal subjects. Loperamide (16 mg) 
or placebo was given orally at -180 min. Insulin was given at 0 min. 
Data are shown as a percentage of the basal value at 0 min in the 
placebo group (100%). The corresponding ACTH value was 4 f  0 pmol/ 
L, and the corresponding cortisol value was 250 + 30 nmol/L. Stars 
indicate times at which a significant difference occurred between lo- 
peramide and placebo treatments by the Scheffe test (*, P < 0.05; art, 
P < 0.01; ****, P < 0.0001). 
2). 
Blood glucose levels and symptoms of hypoglycemia were 
similar in the placebo and loperamide groups (data not 
shown). 
Patients with Gushing’s disease. The mean basal ACTH level 
(0 min) in the patients with Cushing’s disease receiving 
placebo treatment was 16 + 3 pmol/L and similar to that in 
the loperamide group from -180 min up to 0 min. Also, 
after the injection of hCRH, loperamide was not able to 
significantly suppress the ACTH increase, and ACTH levels 
in the placebo and loperamide groups reached peaks of 298 
f 58% and 234 f 54%, respectively, at 30 min. At 120 min, 
ACTH levels in placebo and loperamide groups had returned 
to basal values. Furthermore, there was no significant sup- 
pressive effect of loperamide on the ACTH increase (A30’) 
and AUC (Fig. 3). 
Basal cortisol levels in the placebo (640 f 80 nmol/L) and 
loperamide groups showed a slight decrease from -180 min 
to 0 min, but loperamide had no significant effect at any 
time. Also, after hCRH stimulation, cortisol levels in the 
placebo vs. loperamide groups did not differ significantly 
and reached a maximum values of 150 + 21% and 142 f. 
22%, respectively, at 45 min. At 120 min, values had almost 
declined to basal levels in both groups. In addition, there 
was no significant suppressive effect of loperamide on the 
cortisol increase (A30’) and AUC (Fig. 3). 
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FIG. 3. Effects of loperamide and placebo on plasma ACTH and cor- 
tisol (mean f  SE) before and after a bolus iniection of 100 YE hCRH in 
I  
six patients with Cushing’s disease. Loperamide (16 mg) or placebo was 
given orally at -180 min. hCRH was given at 0 min. Data are shown 
as a percentage of the basal value at 0 min in the placebo group (100%). 
The corresponding ACTH value was 16 + 3 pmol/L, and the corre- 
sponding cortisol value was 640 + 80 nmol/L. At no time did a 
significant difference occur between loperamide and placebo groups, as 
determined by the Scheffe test. 
Patient with secondary adrenal insufficency. The patient’s basal 
ACTH level (0 min) was approximately 2 pmol/L. The max- 
imum values after hCRH injection were reached at 15 min, 
with a pronounced 12-fold increase in ACTH levels. At 120 
min, the prolonged high values had reached a maximum of 
about 9 pmol/L. At no time were hormone measurements 
different between the loperamide and placebo groups (Fig. 
4). Cortisol levels could not be detected, being lower than 30 
nmol/L (Fig. 4). 
No serious side-effects were observed after oral adminis- 
tration of 16 mg loperamide.The only minor complaints were 
constipation for 4 days (two cases) and xerostomia for some 
hours (five cases). 
In vitro studies 
The basal ACTH levels measured in the medium of four 
human corticotropic adenomas differed as follows: 110 
pmol/L (adenoma l), 550 pmol/L (adenoma 2), 2202 pmol/ 
L (adenoma 3), and 6606 pmol/L (adenoma 4). Stimulation 
with hCRH (2 nM) caused a 2-fold increase in ACTH secretion 
in adenomas 1 and 2, while CRH-induced ACTH levels in 
adenomas 3 and 4 were 3 times higher than basal. Loper- 
amide in concentrations of 1 and 10 PM had no significant 
effect on basal or CRH-induced ACTH secretion in any 
adenoma (Fig. 5). 
I . . . .-. .I 
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FIG. 4. Effects of loperamide and placebo on plasma ACTH and cor- 
tisol before and after a bolus injection of 100 pg hCRH in a patient 
with secondary adrenal insufficency due to primary hypothalamic 
failure. Loperamide (16 mg) or placebo was given orally at -180 min. 
CRH was given at 0 min. 
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FIG. 5. Effects of loperamide on basal and CRH-induced ACTH levels 
in the cell culture of four human corticotropic adenomas (mean f  SE; 
n = 4). Data are shown as a percentage of the basal value of the control 
group (100%). The corresponding ACTH value was 2367 + 1483 pmol/ 
L. At no concentration did a significant difference occur between 
loperamide and control groups, as determined by the Scheffe test. 
Discussion 
We have been able to show that loperamide reduces basal 
and CRH-induced ACTH and cortisol levels in normal sub- 
jects. These findings are in agreement with those of Ambrosi 
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et al. (3), who reported a suppressive effect of loperamide on 
basal ACTH levels in normal subjects, and Bochicchio et al. 
(6), who described a suppressive effect of loperamide on 
CRH-induced ACTH secretion in patients with Addison’s 
disease. In addition, we have shown for the first time that 
loperamide is unable to reduce the ACTH increase in the 
insulin-hypoglycemia test. 
The administration of releasing hormones leads to hor- 
mone secretion by activating the anterior pituitary gland 
directly (13). Insulin-induced hypoglycemia activates the 
whole hypothalamo-pituitary-adrenal axis and stimulates su- 
prapituitary centers (14, 15). Insulin-induced hypoglycemia 
provokes peak plasma ACTH levels that are greater than 
those after CRH, arginine vasopressin, or simultaneous CRH 
and arginine vasopressin administration (19). As insulin- 
induced hypoglycemia provokes the secretion of maximally 
stimulating endogenous CRH levels (20), our results might 
reflect a suppressive effect of loperamide on endogenous 
CRH secretion or some other cofactors of corticotropic stim- 
ulation. In the combined pituitary stimulation test, the poten- 
tiating effect of such cofactors on exogenous CRH is missing, 
and the ACTH increase is blunted after loperamide admin- 
istration. In the insulin-hypoglycemia test, the strong stimu- 
lus of hypoglycemia has an overwhelming effect on suprap- 
ituitary structures, and it would appear that loperamide is 
too weak to diminish the secretion of CRH or some other 
cofactors of corticotropic stimulation. On the other hand, a 
pituitary site of action cannot be excluded. First, we do not 
know whether the decline in basal ACTH secretion is me- 
diated by a suppressive effect of loperamide on the cortico- 
trophs themselves or on a hypothetically existing suprapitui- 
tary trigger of basal ACTH secretion. 
It was reported recently that in patients with secondary 
adrenal insufficency who respond to exogenuous CRH with 
a pronounced and prolonged ACTH response, the secondary 
adrenal insufficiency is not caused by a lesion of the pituitary 
gland itself, but by a lesion at a suprapituitary level (21). Our 
data for the patient with secondary adrenal insufficency due 
to a hypothalamic lesion provided confirmation of these 
findings, since although he could not react to insulin-induced 
hypoglycemia, he showed a pronounced and prolonged 
ACTH increase after the CRH stimulation test. Loperamide 
was not able to influence his very low basal and large CRH- 
induced ACTH secretion, while his corticotrophs were still 
able to respond to exogenous stimuli. Although we only 
report a single case and, therefore, it is difficult to extrapolate 
to other cases, these results strongly suggest a suprapituitary 
site of action of loperamide. 
In patients with Cushing’s disease, we could show that 
basal and CRH-induced ACTH levels were not suppressed 
by loperamide; thus, our results are in agreement with those 
of Ambrosi et al. (4), who reported the failure of loperamide 
to suppress basal ACTH levels in these patients. Hypercor- 
tisolism in Cushing’s syndrome is mostly generated by an 
autonomous ACTH-producing pituitary adenoma of mono- 
clonal origin (22). It has been shown that the ACTH increase 
after CRH stimulation is considerably more pronounced in 
patients with Cushing’s disease than in normal controls (13). 
In addition, it has been reported that the main suppressive 
effect of corticosteroid excess on CRH biosynthesis and se- 
cretion takes place at a suprapituitary site (23,24). Therefore, 
it may be possible that the hyperresponsiveness of CRH- 
induced ACTH increase in patients with Cushing’s disease is 
due to an increased sensitivity of corticotrophs to CRH 
resulting from the prolonged absense of negative feedback 
by cortisol. In this context, a suppressive effect of loperamide 
on the already very low endogenous CRH levels in patients 
with Cushing’s disease should not affect their autonomous 
ACTH secretion, while an effect of loperamide at the pitui- 
tary level should have diminished at least the CRH-induced 
ACTH increase. Thus, these data may support the idea of 
loperamide modifying the release of CRH or some other 
cofactors of corticotropic stimulation. 
In addition, we found no significant effect of loperamide 
on basal and CRH-induced ACTH secretion of human cor- 
ticotropic adenomas in vitro. While Lamberts et al. (11) 
reported about a suppressive effect of the p-opiate agonist 
FK 33-824 on ACTH secretion of rat anterior pituitary lobes 
in vitro that was not reversible by naloxone, Rittmaster et al. 
(10) found no effect of morphine on ACTH secretion of 
perifused rat anterior pituitary cells. 
After loperamide administration, we found a significant 
elevation of basal PRL levels, which is in contrast to the 
findings of Ambrosi et al. (4). In agreement with our results, 
different p-opiate agonists have been reported to elevate PRL 
levels in vim (25, 26) and in vitro (27). 
Modulation of the pituitary-adrenal activity by a suprapi- 
tuitary influence of loperamide would require this compound 
to cross the blood-brain barrier. While there are some reports 
to show that loperamide poorly penetrates the blood-brain 
barrier in rats (28) and that it lacks any central opiate-like 
effects in man (29), other researchers found small amounts 
of loperamide after oral application in brain tissue of rats 
(30) and reported an analgesic potency in the mouse hot 
plate test (1). Moreover, loperamide may act at the median 
eminence of the hypothalamus. The observation that loper- 
amide has a high affinity for p-receptors (1, 2) and that there 
exists a high concentration of p-receptors in the hypothala- 
mus (31) coupled with the finding that the p-opiate antago- 
nist naloxone (4) antagonizes the loperamide effect on ACTH 
provide additional evidence to suggest that it probably works 
at a suprapituitary level. 
In summary, loperamide is able to reduce basal and CRH- 
induced ACTH and cortisol levels in normal subjects, but not 
in patients with Cushing’s disease and secondary adrenal 
insufficency due to hypothalamic failure. Furthermore, lo- 
peramide has no effect on insulin-hypoglycemia-induced 
ACTH and cortisol levels in normal subjects. The fact that 
high dose loperamide administration fails to block adreno- 
cortical responsivness to stress in man is of clinical impor- 
tance. One can speculate that there might exist a suprapitui- 
tary site of action of loperamide in man in vim; nevertheless, 
a pituitary site cannot be completely excluded. 
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